Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Stock Downgraded to 'In-Line' by Evercore ISI

NEW YORK ­– Investment banking firm Evercore ISI has downgraded shares of Illumina to an In Line rating, with a price target of $340.

"We are downgrading Illumina to In Line as we see risks and upside surprises as being fairly balanced at current levels," analyst Vijay Kumar wrote in a research note.

"While we are huge fans of Illumina as a fundamental, secular growth company longer term, current valuation causes us to move to the sidelines," he added.

Previously, Evercore had rated the shares at Outperform with a price target of $330.

Kumar said Illumina "had a challenging 2019, with a few curveballs being thrown at the company," including declines in its microarray and direct-to-consumer business, headwinds in China, and delays in population genomics projects. Growth "never materialized," leading to a year of "misses and lowered guidance," Kumar wrote. "As we look towards 2020, we think the company is likely to start the year with a conservative outlook."

In morning trading on the Nasdaq, shares of Illumina were down 1 percent at $328.14.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.